atai Life Sciences reports Q1 for 2022: clinical trials advancing and cash position of $335 million.
Psychedelics
Red Light Holland Successfully Imports 200 Psilocybin iMicrodose Packs, Sold in The Netherlands, Into Canada Under a Third Health Canada Approved Psilocybin Import Permit To cGMP Laboratory
Red Light Holland announces successfully importing its psilocybin microdose packs from the Netherlands into Canada.
MindMed to Host Key Opinion Leader Webinar on Substance Use Disorders and Withdrawal Management
MindMed announces it will host a webinar on substance abuse disorders and withdrawal management that includes prominent experts in this field.
Ketamine Wellness Centers Announces Partnership With The Veterans Administration (VA) in Arizona
Delic Holdings subsidiary, Ketamine Wellness Centers (KWC) announces a partnership with the Veterans Administration to provide ketamine-assisted therapy for veterans with PTSD.
Field Trip and Nue Life Are Collaborating To Bring Psychedelic Therapy Into the Home
Field Trip launches a telehealth version of its ketamine-assisted therapy, via a partnership with Nue Life Health.
Mindset Pharma Progresses Plans for Clinical Trials of its Advanced Pre-Clinical Psychedelic, MSP-1014
Mindset Pharma announces initial planning of its Phase 1 clinical trials for its first family of novel molecules.
Revitalist’s Strategic Initiatives Continue to Exceed Expectations for Execution Giving Company Record High Revenues Since Opening in 2018.
Revitalist Lifestyle and Wellness reports strong month-over-month and year-over-year revenue gains from its ketamine clinic operations.
Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders
Enveric Bioscience announces it is spinning off its cannabinoid R&D pipeline into a stand-alone entity.
Optimi Health Completes Expansion Of On-Site Analytical Laboratory
Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
Mind Medicine Inc announces strong clinical results from its Phase 2 clinical trial using MM-120 for the treatment of Generalized Anxiety Disorder (GAD).
Psychedelic Medicine: The New Frontier In Healthcare, The Big Opportunity In Biopharma
A plethora of drug R&D opportunities. A multitude of badly under-served healthcare treatment markets. A medical "miracle"; an investment pot of gold.
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights
Compass Pathways reports its Q1 for 2022. Net loss of $21.2 million on increased R&D expenses. Cash position of $243.7 million.
Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects on the Brain
Cybin announces more early success with with its Kernel Flow(R) technology to measure the neurological effects of ketamine therapy.
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults
Compass Pathways announces the first-ever study of psilocybin therapy on autistic adults, using COMP360.
Red Light Holland Files International Patent Application for 'Find Your Dose' Customization of Microdosing Kits Based on Biometric and Movement Data
Red Light Holland submits a new patent application for its microdosing kits.